Anticoagulant and defibrinogenating agents in acute ischemic stroke and cerebral venous thrombosis

Seminars in Neurology

Volumn 18, Issue 4, 1998, Pages 461-470

  Meschia, James F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ancrod; Cerebral venous thrombosis; Heparin; Heparinoids; Ischemic stroke; Low molecular weight heparins; Unfractionated heparin

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; DANAPAROID; ENOXAPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN VEIN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EPISTAXIS; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032432408     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040899     Document Type: Review

References (90)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-1276
2. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442
3. Feigin VL, Wiebers DO, Nikitin YP, O'Fallon WM, Whisnant JP. Stroke epidemiology in Novosibirsk, Russia: a population-based study. Mayo Clin Proc 1995;70:847-852
4. Lauria G, Gentile M, Fassetta G, et al. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke 1995;26:1787-1793
5. Ellekjaer H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. Stroke 1997;28:2180-2184
6. D'Alessandro G, Di Giovanni M, Roveyaz L, et al. Incidence and prognosis of stroke in the Valle d'Aosta, Italy. First-year results of a community-based study. Stroke 1992;23:1712-1715
7. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41
8. Madden KP, Karanjia PN, Adams HP Jr, Clarke WR. Accuracy of initial stroke subtype diagnosis in the TOAST study. Trial of ORG 10172 in Acute Stroke Treatment. Neurology 1995;45: 1975-1979
9. Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997;48:1598-1604
10. Sandercock P, Tangkanakul C. Very early prevention of stroke recurrence. Cerebrovasc Dis 1997;7:10-15
11. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238-248
12. Biller J, Hingtgen WL, Adams HP Jr, Smoker WR, Godersky JC, Toffol GJ. Cervicocephalic arterial dissections. A ten-year experience. Arch Neurol 1986;43:1234-1238
13. Biller J, Adams HP Jr, Boarini D, Godersky JC, Smoker WR, Kongable G. Intraluminal clot of the carotid artery. A clinical-angiographic correlation of nine patients and literature review. Surg Neurol 1986;25:467-477
14. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119-124
15. Bounds JV, Wiebers DO, Whisnant JP, Okazaki H. Mechanisms and timing of deaths from cerebral infarction. Stroke 1981;12: 474-477
16. Samama MM, Desnoyers PC, Conard J, Bousser MG. Acute ischemic stroke and heparin treatments. Thromb Haemost 1997; 78:173-179
17. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery 1978; 83:354-358
18. Turpie AG, Delmore T, Hirsh J, et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thromb Res 1979;15:611-616
19. Grotta J, Ackerman R, Correia J, Fallick G, Chang J. Whole blood viscosity parameters and cerebral blood flow. Stroke 1982;13: 296-301
20. Cavestri R, Radice L, Ferrarini F, Longhini M, Longhini E. Influence of erythrocyte aggregabilily and plasma fibrinogen concentration on CBF with aging. Acta Neurol Scand 1992;85: 292-298
21. Nobili F, Rodriguez G, Marenco S, Gambara M, Stubinski BM, Rosadini G. Fibrinogen and cerebral blood flow: a correlative study. Clin Hemorheol 1993;13:245-252
22. Italian Acute Stroke Study Group. Haemodilution in acute stroke: results of the Italian haemodilution trial. Lancet 1988;1:318-321
23. Matthews WB, Oxbury JM, Grainger KM, Greenhall RC. A blind controlled trial of dextran 40 in the treatment of ischaemic stroke. Brain 1976;99:193-206
24. Walzl M, Lechner H, Walzl B, Schied G. Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 1993;24:1447-1451
25. Culebras A, Kase CS, Masdeu JC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke. A report of the Stroke Council, American Heart Association. Stroke 1997;28:1480-1497
26. Furlan AJ, Cavalier SJ, Hobbs RE, Weinstein MA, Modic MT. Hemorrhage and anticoagulation after nonseptic embolic brain infarction. Neurology 1982;32:280-282
27. Lodder J, van der Lugt PJM. Evaluation of the risk of immediate anticoagulant treatment in patients with embolic stroke of cardiac origin. Stroke 1983;14:42-46
28. Calandre L, Ortega JF, Bermejo F. Anticoagulation and hemorrhagic infarction in cerebral embolism secondary to rheumatic heart disease. Arch Neurol 1984;41:1152-1154
29. Ramirez-Lassepas M, Quinones MR, Nino HH. Treatment of acute ischemic stroke. Open trial with continuous intravenous heparinization. Arch Neurol 1986;43:386-390
30. Haley EC Jr, Kassell NF, Torner JC. Failure of heparin to prevent progression in progressing ischemic infarction. Stroke 1988; 19:10-14
31. Rothrock JF, Dittrich HC, McAllen S, Taft BJ, Lyden PD. Acute anticoagulation following cardioembolic stroke. Stroke 1989; 20:730-734
32. Camerlingo M, Casto L, Censori B, et al. Immediate anticoagulation with heparin for first-ever ischemic stroke in the carotid artery territories observed within 5 hours of onset. Arch Neurol 1994;51:462-467
33. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral embolic infarction: a safety study. Neurology 1995;45:861-865
34. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology 1993;43: 1298-1303
35. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996;46:341-345
36. Melo TP, Bogousslavsky J, Regli F, Janzer R. Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy. Eur Neurol 1993;33:9-12
37. Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996;46:1751-1754
38. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22-1996. Cerebral hemorrhage in a 69-year-old woman receiving warfarin [clinical conference]. N Engl J Med 1996;335:189-196
39. Chang JC. White clot syndrome associated with heparin-induced thrombocytopenia: a review of 23 cases. Heart Lung 1987;16: 403-407
40. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993; 305:208-215
41. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995;89:431-439
42. AbuRahma AF, Boland JP, Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg 1991;162:175-179
43. Ramirez-Lassepas M, Cipolle RJ, Rodvold KA, et al. Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984;34:736-740
44. Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemost 1986;55:37-39
45. Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost 1985; 11: 326-329
46. Gouault-Heilmann M, Huet Y, Adnot S, et al. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis 1987;17:134-140
47. Peters FP, Doevendans PA, Erdkamp FL, Van Der Ent FW, De Heer F. Low molecular weight heparin-induced thrombocytopenia and thrombosis [letter]. Eur J Haematol 1996;56:329-330
48. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73: 1592-1596
49. Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996;61:920-924
50. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554-561
51. Greinacher A, Drost W, Michels I, et al. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Hematol 1992;64:40-42
52. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992;22:85-91
53. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Br J Haematol 1994;86:425-426
54. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108: 258S-275S
55. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698
56. Meuleman DG, Hobbelen PM, van Dedem G, Moelker HC. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982;27: 353-363
57. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983;14:668-676
58. Duke RJ, Bloch RF, Turpie AG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986;105:825-828
59. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581
60. Dennis M, Wellwood I, O'Rourke S, MacHale S, Warlow C. How reliable are simple questions in assessing outcome after stroke? Cerebrovasc Dis 1997;7:19-21
61. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989;19:245-250
62. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990;16:25-33
63. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333:1588-1593
64. Turpie AG, Levine MN, Hirsh J, et al. Double-blind randomised trial of Org 10172 low- molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526
65. Ten Cate H, Henny CP, Buller HR, Ten Cate JW, Magnani HN. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984;15:268-270
66. Biller J, Massey EW, Marler JR, et al. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. Neurology 1989;39:262-265
67. Massey EW, Biller J, Davis JN, et al. Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. Stroke 1990;21:1289-1292
68. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279:1265-1272
69. Reid HA, Thean PC, Chan KE, Baharom AR. Clinical effects of bites in Malayan viper (ancistrodon rhodostoma). Lancet 1963: 617-621
70. Reid HA, Chan KE, Thean PC. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963: 621-626
71. Esnouf MP, Tunnah GW. The isolation and properties of the thrombin-like activity from Ancistrodon rhodostoma venom. Br J Haematol 1967;13:581-590
72. Burkhart W, Smith GF, Su JL, Parikh I, LeVine H III. Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of Akistrodon rhodostoma. FEBS Lett 1992;297:297-301
73. Illig KA, Ouriel K. Ancrod: understanding the agent. Semin Vasc Surg 1996;9:303-314
74. Hossmann V, Heiss WD, Bewermeyer H, Wiedemann G. Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983; 40:803-808
75. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992;117:371-375
76. Kannel WB, RB DA, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-466
77. Olinger CP, Brott TG, Barsan WG, et al. Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med 1988;17:1208-1209
78. Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325
79. Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-1759
80. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992;10:87-111
81. Southwick FS, Richardson EP Jr, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) 1986;65:82-106
82. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-1730
83. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996;27:1721-1723
84. Larkey D, Williams CR, Fanning J, Hilgers RD, Graham DR, Fortin CJ. Fatal superior sagittal sinus thrombosis associated with internal jugular vein catheterization. Am J Obstet Gynecol 1993;169:1612-1614
85. Wechsler B, Vidailhet M, Piette JC, et al. Cerebral venous thrombosis in Behcet's disease: clinical study and long-term follow-up of 25 cases. Neurology 1992;42:614-618
86. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600
87. Enevoldson TP, Ross Russell RW. Heparin treatment in sinus venous thrombosis [letter]. Lancet 1991;338:1153-1154
88. Grond M, Rudolf J, Schmülling S, Stenzel C, Neveling M, Heiss W-D. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. Arch Neurol 1998;55:466-469
89. Grond M, Rudolf J, Stenzel C, Heiss W-D. Risk of immediate heparin after rt-PA therapy in acute ischemic stroke. Cerebrovasc Dis 1997;7:318-323
90. Horowitz M, Purdy P, Unwin H, et al. Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995;38:58-67